Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study

Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Recurrence after resection of colorectal liver metastases (CRLMs), presumably caused by VEGF-mediated outgrowth of micrometastases, might decrease when VEGF is inhibited. This study examines the effic...

Full description

Bibliographic Details
Main Authors: Nikol Snoeren, Richard van Hillegersberg, Sander B. Schouten, Andre M. Bergman, Erikv van Werkhoven, Otilia Dalesio, Rob A.E.M. Tollenaar, Henk M. Verheul, Joost van der Sijp, Inne H.M. Borel Rinkes, E.E. Voest
Format: Article
Language:English
Published: Elsevier 2017-02-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558616301701

Internet

http://www.sciencedirect.com/science/article/pii/S1476558616301701

Similar Items